SCHEMBL2992316

SCHEMBL2992316

CC(C)C(C)(c1ccc(OCc2ccccn2)cc1)c1ccc(-c2noc(CN3CCOCC3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 2/20 0.48
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
TSHR P16473 3/20 0.47
MAPK14 Q16539 1/20 0.44
SMO Q99835 1/20 0.44
ALOX5AP P20292 1/20 0.44
NAMPT P43490 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 1/20 0.42
GLP1R P43220 3/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707836 0.93 ALOX5AP (0.51) SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10
SCHEMBL707835 0.93 ALOX5AP (0.51) SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10
SCHEMBL480213 0.92 ALOX5AP (0.54) SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10
SCHEMBL2995851 0.85 NPC1 (0.48) NPC1RAB9AALDH1A1MAPTMAPK14
SCHEMBL2993389 0.84 ALOX5AP (0.49) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL2994239 0.84 ALOX5AP (0.51) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3000650 0.82 ALOX5AP (0.56) NPC1RAB9AMAPTMAPK14SMO
SCHEMBL3884509 0.81 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10
SCHEMBL3884511 0.81 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10
SCHEMBL2988831 0.81 ALOX5AP (0.52) SMN1; SMN2NPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2546232-A1 Diphenyl Substituted Alkanes Merck Sharp & Dohme Corp. (US) 2013-01-16 EP disclosed
EP-2546232-A1 Diphenyl Substituted Alkanes Merck Sharp & Dohme Corp. (US) 2013-01-16 EP disclosed
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES MERCK SHARP & DOHME CORP. 2010-07-29 US disclosed
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES MERCK SHARP & DOHME CORP. 2010-07-29 US disclosed
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES MERCK SHARP & DOHME CORP. 2010-07-29 US disclosed
WO-2008156721-A1 DIPHENYL SUBSTITUTED ALKANES MERCK & CO., INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES ALOX5, ALOX15, ALOX15B SMN1; SMN2 4219/4885NPC1 603/4885RAB9A 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.